Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-09-23

FDA Approved: LEFLUNOMIDE — Supplemental Application (Alembic Pharmaceuticals Limited)

View source ↗

Summary

FDA approved a supplemental application for Leflunomide from Alembic Pharmaceuticals Limited, confirming continued approval of the generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Leflunomide (Leflunomide)

Snippet

SUPPL AP for LEFLUNOMIDE (LEFLUNOMIDE)